DIMERx Secures Second NIH Award to Advance DMX-201 for Sickle Cell Disease
San Francisco, California--(Newsfile Corp. - September 22, 2026) - DIMERx, Inc., a clinical-stage biopharmaceutical company developing novel dimer-based therapeutics, today announced that it has received a Small Business Innovation Research (SBIR) award from the National Heart, Lung, and Blood Institute (NHLBI) to advance DMX-201 for sickle cell disease (SCD). DMX-201 has the potential to become a first-line therapy for acute chest syndrome (ACS), helping reduce acute respiratory distress,...
2026-09-22 9:00 AM EDT
DIMERx Preclinical Data Confirms DMX-101 Non-Addictive Profile: No Reinforcement, No Dependence
San Francisco, California--(Newsfile Corp. - May 12, 2026) - DIMERx, Inc. ("DIMERx" or "the Company") is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug misuse and dependence, with a portfolio of first-in-class, dimer-based pain therapeutics engineered to deliver effective analgesia without the addiction liabilities of conventional opioids. In June 2025, DIMERx was awarded a NIH HEAL Initiative grant to advance its DMX-101 program. The...
2026-05-12 9:00 AM EDT
Jeffrey W. Sherman, MD, Joins DIMERx Board to Advance Next-Generation, Non-Addictive Pain Therapies
San Francisco, California--(Newsfile Corp. - March 3, 2026) - DIMERx, Inc. ("DIMERx" or "the Company"), is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug abuse and dependence, with a portfolio of first-in-class, dimer-based pain therapeutics engineered to deliver effective analgesia without the addiction liabilities of conventional opioids. The Company announced the appointment of Jeffrey W. Sherman, MD, FACP, to its Board of Directors. Dr....
2026-03-03 9:00 AM EST